Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Stepping Up: Why Participate in Clinical Research?
Beyond the Endpoint
32 minutes 13 seconds
7 months ago
Stepping Up: Why Participate in Clinical Research?
In this episode, cancer survivor Katie Ortman-Doble opens up about her journey through clinical research and why she chose to participate. Hosts Emily O’Brien and Manesh Patel, joined by Jenny Cook, talk about the life-saving potential of clinical trials and the real impact they have on patients and science.
Hear Katie’s inspiring story and the reasons behind her decision to join a trial.
🔗 Access resources related to this episode https://dcri.org/blog/ep-7-stepping-why-participate-clinical-research
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
